DrugPatentWatch Database Preview
Intersect Ent Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for INTERSECT ENT INC, and when can generic versions of INTERSECT ENT INC drugs launch?
INTERSECT ENT INC has one approved drug.
There are thirteen US patents protecting INTERSECT ENT INC drugs.
There are forty-seven patent family members on INTERSECT ENT INC drugs in twelve countries and two supplementary protection certificates in two countries.
Summary for Intersect Ent Inc
| International Patents: | 47 |
| US Patents: | 13 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Intersect Ent Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 8,025,635 | Start Trial | Y | Start Trial | |||
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 10,357,640 | Start Trial | Start Trial | ||||
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 8,109,918 | Start Trial | Start Trial | ||||
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 7,662,141 | Start Trial | Start Trial | ||||
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 7,713,255 | Start Trial | Start Trial | ||||
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 7,544,192 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Intersect Ent Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 102573981 | Start Trial |
| Japan | 6757761 | Start Trial |
| Canada | 2518960 | Start Trial |
| European Patent Office | 2429624 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2010132648 | Start Trial |
| Australia | 2009276505 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Intersect Ent Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0112669 | 96C0002 | Belgium | Start Trial | PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622 |
| 0548114 | SPC/GB97/064 | United Kingdom | Start Trial | PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
